Eli Lilly CEO Eyes Larger Deals Across New Disease Areas
Eli Lilly CEO David Ricks has indicated that the pharmaceutical company is exploring new acquisition opportunities larger than recent deals and in different disease areas. Speaking to Bloomberg, Ricks emphasized a focus on infectious diseases and women's health as potential targets for expansion through strategic acquisitions. The comments come amid ongoing efforts by Eli Lilly to grow its portfolio beyond core therapeutic areas such as diabetes and oncology. The company has previously made several smaller deals but is now looking at larger opportunities that could reshape its product pipeline and market position in the long term.
Tickers: $LLY